X

Trial Profile

Dose-ranging study of pradefovir in patients with compensated hepatitis B

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Sep 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pradefovir (Primary) ; Adefovir dipivoxil; Tenofovir disoproxil fumarate
Indications Hepatitis B
Focus Adverse reactions; Therapeutic Use
Sponsors Bausch Health Companies; Valeant Pharmaceuticals International

Most Recent Events

06 Sep 2021 Results (Week 24) assessing efficacy and safety of oral pradefovir in Patients with chronic hepatitis B, published in the Clinical Infectious Diseases.
03 Jul 2012 Extension study data integrated (NCT00230490).
21 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com